Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial.
Bian X, Gu W, Zhang X, Xie L, Wang S, Shi B, Sun T, Wei S, Weng Z, Xia S, Han B, Xu Z, Xing J, Zhang D, Xu D, Du C, He C, Wang Q, Yang X, Lian J, Wang W, Ye D.
Bian X, et al.
Med. 2024 Oct 14:S2666-6340(24)00376-3. doi: 10.1016/j.medj.2024.09.009. Online ahead of print.
Med. 2024.
PMID: 39419035